Approximately 80% of lung cancers are NSCLC9, and Ras signaling pathway is activated in nearly half of NSCLC patients due either to amplification of EGFR or to activating mutations in EGFR or KRAS3. This evidence concerns the gene EGFR and lung carcinoma.